Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways

Abstract excerpt

OBJECTIVES: Belimumab is a putative disease-modifying agent in systemic lupus erythematosus (SLE), yet the molecular underpinnings of its effects and the ability to predict early clinical response remain unexplored. To address these, we undertook a longitudinal, in-depth blood transcriptome study. METHODS: RNA-sequencing was performed in the blood of active SLE patients at baseline and following 6 months of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to interferon and immune responses
• Share to Single-cell and spatial transcriptomics